Cardiovascular disease risk and pathophysiology in South Asians: can longitudinal multi-omics shed light?

Abstract

Cardiovascular disease (CVD) is the leading cause of mortality in South Asia, with rapidly increasing prevalence of hypertension, type 2 diabetes (T2DM) and hyperlipidemia over the last two decades. Atherosclerotic CVD (ASCVD) affects South Asians earlier in life and at lower body weights, which is not fully explained by differential burden of conventional risk factors. Heart failure (HF) is a complex clinical syndrome of heterogeneous structural phenotypes including two major clinical subtypes, HF with preserved (HFpEF) and reduced ejection fraction (HFrEF). The prevalence of HF in South Asians is also rising with other metabolic diseases, and HFpEF develops at younger age and leaner body mass index in South Asians than in Whites. Recent genome-wide association studies, epigenome-wide association studies and metabolomic studies of ASCVD and HF have identified genes, metabolites and pathways associated with CVD traits. However, these findings were mostly driven by samples of European ancestry, which may not accurately represent the CVD risk at the molecular level, and the unique risk profile of CVD in South Asians. Such bias, while formulating hypothesis-driven research studies, risks missing important causal or predictive factors unique to South Asians. Importantly, a longitudinal design of multi-omic markers can capture the life-course risk and natural history related to CVD, and partially disentangle putative causal relationship between risk factors, multi-omic markers and subclinical and clinical ASCVD and HF. In conclusion, combining high-resolution untargeted metabolomics with epigenomics of rigorous, longitudinal design will provide comprehensive unbiased molecular characterization of subclinical and clinical CVD among South Asians. A thorough understanding of CVD-associated metabolomic profiles, together with advances in epigenomics and genomics, will lead to more accurate estimates of CVD progression and stimulate new strategies for improving cardiovascular health.

From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators

“…A recent study integrated proteomic and transcriptomics from immune cells identified activated T-cells and macrophages in atherosclerotic plaques and a greater proportion of exhausted T-cells in symptomatic patients though further research is needed to establish whether exhaustion occurs before or after the cardiovascular event [145]. Longitudinal study designs in multi-omics can aid in resolving the order of molecular events [146], and they have recently been used to resolve the temporal fate of immune cell states during the course of COVID-19 and discover inflammatory signatures preceding fatal outcomes [147,148]. Longitudinal sampling can also identify patterns within and between 'omics layers that vary over time.…”

Defining atherosclerotic plaque biology by mass spectrometry-based omics approaches

“…The environmental exposures can modify the gene expression levels through epigenetic mechanisms, and this modification can be inherited across cell generations to exert a long-term impact on the development of CVD. 5 Atherogenesis is a prolonged multistep process that involves endothelial dysfunction and lipoprotein retention on the arterial walls, followed by lymphocyte infiltration, inflammation, foam cell formation, plaque buildup and thrombosis. The fibrous cap which forms around the plaque acts as a protective barrier between the prothrombic atheroma and the platelets in the bloodstream.…”

Identifying latent comorbidity patterns in adults with perceived cognitive impairment: Network findings from the behavioral risk factor surveillance system

“…Pattern : Heart attack, coronary heart disease, stroke, and kidney disease CVD includes a number of cardiac conditions including (a) coronary heart disease, either angina or heart attack, (b) stroke, which is caused by a blockage of a blood clot (known as ischemic stroke) or the rupture of a blood vessel and bleeding (known as hemorrhagic stroke), and (c) peripheral vascular disease which refers to the obstruction of the large blood vessels that supply blood to the arms and legs (51).…”